Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqihuayu Decoction is a Traditional Chinese Medicine (TCM) herbal formulation investigated for the treatment of acute ischemic stroke. The formula is based on the therapeutic principle of "Yiqi Huayu," which involves replenishing Qi and resolving blood stasis to restore neurological function and protect brain tissue from ischemic damage. It is typically composed of multiple botanical ingredients, including *Astragalus membranaceus*, *Salvia miltiorrhiza*, and *Ligusticum chuanxiong*, which are thought to exert neuroprotective effects through anti-inflammatory, antioxidant, and microcirculation-enhancing pathways. The PHYSIS trial (NCT04433403), led by researchers such as Ying Gao at Dongzhimen Hospital (Beijing University of Chinese Medicine), aims to characterize the specific pharmacodynamic substances within the decoction and evaluate its clinical efficacy in improving neurological outcomes during the acute phase of stroke.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yiqihuayu decoction.